Results 141 to 150 of about 10,181,415 (248)
Anorectal Dysfunction in Systemic Sclerosis: Clinical Phenotypes and Functional Patterns
Arthritis Care &Research, EarlyView.Objective The aim of this study was to characterize specific physiologic defects in anorectal dysfunction in systemic sclerosis (SSc) using anorectal manometry (ARM), evaluate associations with gastrointestinal (GI) and extraintestinal clinical phenotypes, and explore potential serologic markers for risk stratification.
Timothy Kaniecki +6 more
wiley +1 more source
From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis
Arthritis Care &Research, EarlyView.Spondyloarthritis (SpA) is a group of chronic inflammatory diseases encompassing axial and peripheral forms, with up to 20% of patients developing symptoms before age 16. Despite this substantial pediatric burden, treatment options for juvenile‐onset SpA (JSpA), particularly those with axial disease (axJSpA), remain limited.
Pamela F. Weiss +9 more
wiley +1 more source
Arthritis Care &Research, EarlyView.Objective Orofacial manifestations are significantly impactful in patients with systemic sclerosis (SSc) yet remain understudied, with no dedicated clinical guidelines to inform their management. Methods An international online survey comprised38 questions addressing orofacial manifestations of SSc, including patients’ confidence in their treating ...
Eleni Deligianni +4 more
wiley +1 more source
Arthritis Care &Research, EarlyView.Objective Elevated C‐reactive protein (CRP) levels in systemic sclerosis (SSc) have been linked with severe disease and worse survival, but the role of platelet levels remains unclear. This study examined whether elevated platelet levels, CRP levels, or both are associated with disease severity, progression, and survival in SSc.
Brian S. Lee +4 more
wiley +1 more source
Clinical details of imatinib responders and non-responders.
, 2015 Clinical details of imatinib responders and non-responders.
Shantashri Vaidya (687214) +4 more
core +1 more source
Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS‐DAI)
Arthritis Care &Research, EarlyView.Objective Vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS) syndrome is characterized by a complex spectrum of inflammatory and hematologic manifestations. Clinical research to identify effective therapies is urgently needed but is hindered by the lack of validated outcome measures.
Kevin Byram +25 more
wiley +1 more source
Immune checkpoint-based biomarkers for therapeutic response in patients with multiple sclerosis
Frontiers in ImmunologyIntroductionAlthough numerous disease-modifying treatments have been introduced for multiple sclerosis (MS), approximately 25% of patients experience therapeutic failure.
MariPaz López-Molina +15 more
doaj +1 more source
Arthritis Care &Research, EarlyView.Objective Despite guideline recommendations, long‐term glucocorticoid (GC) use is common in rheumatoid arthritis (RA). We conducted a clinician survey nested within a large registry to identify patient and clinician factors associated with GC use. Methods Clinicians contributing patients to the CorEvitas Rheumatoid Arthritis Registry were surveyed ...
Michael D. George +7 more
wiley +1 more source
Caregiver Perspectives on the Burden of Disease and Treatment in Uncontrolled Gout
Arthritis Care &Research, EarlyView.Objective Uncontrolled gout (UG) refers to persistently elevated serum urate (SU) levels >6 mg/dL and ongoing gout symptoms despite use of urate‐lowering therapy (ULT). The objective of this study was to evaluate the burden associated with informal caregiving for individuals with UG.
Angelo Gaffo +6 more
wiley +1 more source
Overall Survival Difference between COXEN Predicted Responders vs. Non-Responders.
, 2012 (A) Kaplan Meier survival plot of Dressman-119 cohort. (B) Kaplan Meier survival plot of UVA-55 cohort. The survival curves of patients predicted to be responders (Red) and non-responders (Green) showed significant differences between COXEN predicted ...
J. Stuart Ferriss (184384) +7 more
core +1 more source